What is the Roivant 'Vant' model and how does it create value?

Traditional pharma holding company problem: a large pharmaceutical company trying to develop drugs in multiple therapeutic areas faces management bandwidth challenges — senior management must simultaneously oversee cardiovascular, oncology, neurology, immunology, and other therapeutic areas; each area requires deep expertise; resources (capital, management time) are allocated across competing priorities. Roivant's Vant solution: Roivant creates independent subsidiary companies ('Vants') for each therapeutic focus area; Myovant Sciences focused on reproductive medicine and prostate cancer; Immunovant focuses on FcRn inhibition in autoimmune disease; Aruvant Sciences focuses on sickle cell gene therapy; each Vant has its own CEO, board, and management team with deep therapeutic area expertise; each Vant can raise its own capital independently (from venture capital, public offering, or pharmaceutical partnerships). Value creation mechanisms: specialized focus — each Vant management team focuses exclusively on their therapeutic area, potentially making better decisions than a generalist pharmaceutical management team; independent capitalization — Vants raise capital from third-party investors, funding development without full dilution to Roivant shareholders; Roivant retains a majority (60-70%) ownership stake in each Vant while accessing external capital for the Vant's development program; talent attraction — therapeutic area specialists are more motivated by a focused company than a division of a large pharma company; successful Vant exit — if a Vant achieves an acquisition or standalone IPO success (as Myovant did before being acquired by Sumitomo Pharma), Roivant's stake is monetized. Historical precedent: Myovant Sciences (developed relugolix for prostate cancer and uterine fibroids) became a commercial success and was acquired by Sumitomo Pharma for approximately $2.9 billion; this demonstrated the Vant model's ability to create significant value from a single successful program.

What is an FcRn inhibitor and why is Immunovant's program important?

FcRn biology: the neonatal Fc receptor (FcRn) is a protein that extends the half-life of IgG antibodies in the blood; normally, proteins in the blood are taken up by cells and degraded; FcRn rescues IgG antibodies from degradation by binding them in acidic endosomes and recycling them back to the blood; without FcRn, IgG antibodies would have a half-life of only about 3 days instead of the normal 21 days. Autoimmune mechanism: in autoimmune diseases (myasthenia gravis, thyroid eye disease, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy), the patient's immune system produces pathogenic autoantibodies (IgG antibodies that attack the patient's own tissues); these autoantibodies are extended in the blood by the same FcRn recycling mechanism that extends all IgG antibodies. FcRn inhibitor therapy: drugs that block FcRn prevent the recycling of all IgG antibodies (including pathogenic autoantibodies), dramatically reducing the concentration of disease-causing autoantibodies in the blood; argenx's efgartigimod (Vyvgart) became the first approved FcRn inhibitor (for myasthenia gravis in 2021) and demonstrated this mechanism's potent clinical activity; Immunovant's IMVT-1402 is a next-generation FcRn inhibitor that may offer subcutaneous dosing, shorter infusion times, or once-monthly dosing advantages over approved FcRn inhibitors. Commercial significance: the autoimmune disease market (myasthenia gravis, thyroid eye disease, CIDP, pemphigus vulgaris, ITP) is large and growing; FcRn inhibitors could become a broadly applicable treatment across many IgG-mediated autoimmune conditions; the approved efgartigimod generated billions in revenue for argenx; Immunovant's IMVT-1402 competes in this high-value space.

What is NRG1 gene fusion and why is Zenocutuzumab important?

NRG1 biology: Neuregulin-1 (NRG1) is a growth factor that binds to the HER3 receptor on cell surfaces; HER3 has no intrinsic kinase activity (it cannot signal independently) but signals by partnering with HER2; when NRG1 binds HER3, HER3 dimerizes (pairs) with HER2, activating HER2's kinase and triggering downstream cell survival and proliferation signals. NRG1 gene fusions: in approximately 1-3% of cancers (NSCLC, pancreatic, breast, cholangiocarcinoma), chromosomal rearrangements create fusion genes that produce an abnormal NRG1 protein fused to another protein; these NRG1 fusion proteins are overproduced and constitutively activate the HER3/HER2 pathway without requiring normal growth factor signaling; this creates an oncogenic driver — a constantly active growth signal that drives tumor growth. Why it was undruggable: NRG1 fusions activate HER3 by binding to it (a ligand activation); traditional HER2 inhibitors (trastuzumab, pertuzumab) don't effectively block NRG1-driven HER3 activation because the activation occurs on the extracellular domain of HER3 that these antibodies don't block; NRG1-driven tumors are resistant to EGFR inhibitors and other common oncology targeted therapies. Zenocutuzumab's mechanism: Merus's Zenocutuzumab is designed as a bispecific antibody — one arm binds HER2 and the other arm binds HER3; the HER3-binding arm specifically blocks NRG1 from binding to HER3, preventing the activation of the HER3/HER2 pathway; simultaneously, the HER2-binding arm inhibits HER2 signaling; this dual blockade effectively shuts down the NRG1 fusion driver. Clinical significance: early clinical data in NRG1 fusion NSCLC and pancreatic cancer showed meaningful objective response rates in patients with no other standard treatment options; FDA has designated Zenocutuzumab as a Breakthrough Therapy for NRG1 fusion tumors; this accelerated designation can expedite approval for a genuinely important cancer therapy.

Last updated: August 4, 2026

brimindinvest.com / compare / roiv-vs-merusLIVE

ROIV

Roivant Sciences Ltd. · Healthcare - Biotech Holding Company

$34.08

-3.00% this month

VERSUS

⟷

COMPARE

MRUS

Merus N.V. · Healthcare - Clinical-Stage Biotech (Bispecific Antibodies)

N/A

N/A this month

Scoreboard verdict

Across AI score, momentum, valuation, upside, operating margin

ROIV

0

MRUS

0

MIXED SETUP

Comparison scoreboard

MIXED SETUP

AI Score

ROIV 46.5

MRUS N/A

1Y Return

ROIV +196.05%

MRUS N/A

Fwd P/E

ROIV -21.84

MRUS N/A

Target Up.

ROIV +14.25%

MRUS N/A

Op. Margin

ROIV N/A

MRUS N/A

Metrics last refreshed: 8/4/2026

Quick take

ROIV vs MRUS Stock Comparison: AI Score, Valuation, Performance and Upside

ROIV (Roivant Sciences) and MRUS (Merus N.V.) are both innovative clinical-stage biotech companies with differentiated business models — Roivant uses its Vant holding company structure to incubate multiple therapeutic area specialists with Vtama as a commercial product anchor, while Merus is a bispecific antibody specialist using its Biclonics platform for first-in-class programs like Zenocutuzumab for NRG1 fusion cancers with major pharma partnerships.

ROIV vs MRUS is biotech holding company with commercial Vtama psoriasis/dermatitis revenue and diversified Vant pipeline (Roivant's Vtama commercial launch, Immunovant FcRn inhibitor, and Vant model spreading clinical risk across therapeutic areas — managing Vtama commercial underperformance and conglomerate valuation complexity) versus bispecific antibody technology specialist with first-in-class NRG1 fusion cancer program and major pharma validation (Merus's Zenocutuzumab rare cancer approach, Incyte/Lilly partnerships, and Biclonics platform breadth — navigating rare disease market size limitations and bispecific antibody competitive intensity).

Live analysis · updated 8/4/2026

ROIV and MRUS are closely matched — they split the tracked metrics evenly.

Normalized 1Y performance

ROIV

MRUS

Not enough data to chart yet.

Recent returns

ROIV

MRUS

Analyst price targets & sentiment

ROIV · 11 analysts

STRONG BUYHOLDSTRONG SELL

Strong Buy (1.3/5.0)

Price target range

analyst low$34.00
analyst high$42.00
analyst mean$38.91
current price$34.08

+14.3% upside to analyst mean

MRUS

Price target data unavailable

N/A

Who should consider this stock?

ROIV may suit investors who:

→Want diversified biotech exposure through a holding company model with commercial revenues (Vtama) and multiple clinical-stage programs across different therapeutic areas through the Vant structure
→Value Immunovant's FcRn inhibitor program as addressing a high-value autoimmune disease franchise similar to what argenx achieved with efgartigimod
→Believe Roivant's capital-efficient Vant model for accessing multiple therapeutic programs through one public company share is an innovative approach to biotech holding company investing

MRUS may suit investors who:

→Want exposure to the bispecific antibody drug modality through a platform company with multiple proprietary and partnered programs validated by Eli Lilly and Incyte partnerships
→Believe Zenocutuzumab's first-in-class approach to NRG1 fusion cancers addresses a genuine rare cancer unmet need that could qualify for accelerated approval and support a premium commercial product launch
→See Merus's Biclonics platform as creating a sustainable pipeline of bispecific antibody candidates across diverse target combinations in oncology

Performance & AI score

Performance & AI score
Metric	ROIV	MRUS
AI score	46.5	N/A
AI rank	#637	N/A
Latest close	$34.08	N/A
1M return	-3.00%	N/A
6M return	+55.31%	N/A
1Y return	+196.05%	N/A

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

$10,000 invested — hypothetical growth (dividends reinvested)
Period	ROIV	MRUS
1Y ago	$29.6K (+196.0%) started 2025-08-04	N/A
5Y ago	$34.42K (+244.2%) started 2021-08-04	N/A
10Y ago	$32.76K (+227.6%) started 2020-12-08	N/A

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Valuation & upside potential
Metric	ROIV	MRUS
Market cap	$24.6B	N/A
Trailing P/E	N/A	N/A
Forward P/E	-21.84	N/A
Price/Sales	2978.40	188.92
EV/Revenue	2487.50	N/A
Analyst target	$38.91	N/A
Target upside	+14.25%	N/A

Growth, profitability & risk

Growth, profitability & risk
Metric	ROIV	MRUS
Revenue growth	-66.70%	N/A
Earnings growth	N/A	N/A
EPS growth	N/A	N/A
FCF margin	-13202.00%	N/A
Operating margin	N/A	N/A
Profit margin	0.00%	N/A
ROIC proxy	-7.59%	N/A
Return on equity	-7.59%	N/A
Dividend yield	0.00%	N/A
Beta	1.13	0.63
Debt/equity	2.03	N/A
Current ratio	18.37	N/A
Quick ratio	18.00	N/A

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

ROIV max drawdown12.84%

MRUS max drawdownN/A

ROIV max wkly drop8.11%

MRUS max wkly dropN/A

5Y risk snapshot

ROIV max drawdown79.22%

MRUS max drawdownN/A

ROIV max wkly drop36.10%

MRUS max wkly dropN/A

10Y risk snapshot

ROIV max drawdown79.22%

MRUS max drawdownN/A

ROIV max wkly drop36.10%

MRUS max wkly dropN/A

Performance metrics by period

Performance metrics by period
Period	Metric	ROIV	MRUS
1Y	Growth	+196.05%	N/A
	CAGR	+196.27%	N/A
	Sharpe ratio	2.67	N/A
	Max drawdown	12.84%	N/A
	Max daily drop	4.72%	N/A
	Max wkly drop	8.11%	N/A
5Y	Growth	+244.19%	N/A
	CAGR	+28.05%	N/A
	Sharpe ratio	0.63	N/A
	Max drawdown	79.22%	N/A
	Max daily drop	16.11%	N/A
	Max wkly drop	36.10%	N/A
10Y	Growth	+227.64%	N/A
	CAGR	+23.36%	N/A
	Sharpe ratio	0.57	N/A
	Max drawdown	79.22%	N/A
	Max daily drop	16.11%	N/A
	Max wkly drop	36.10%	N/A

Business comparison

Business comparison
Category	ROIV	MRUS
Company	Roivant Sciences Ltd.	Merus N.V.
Sector	Healthcare - Biotech Holding Company	Healthcare - Clinical-Stage Biotech (Bispecific Antibodies)
Industry	N/A	N/A
Core business	Roivant Sciences is a biopharmaceutical company with a distinctive 'Vant' business model — rather than developing drugs through a single organization, Roivant creates independent subsidiary companies ('Vants') each focused on a specific therapeutic area, raised with their own capital, and led by specialized management teams. Roivant's subsidiaries have included Myovant Sciences (acquired by Sumitomo Pharma), Kiniksa Pharmaceuticals, Immunovant, Aruvant Sciences, and others. Roivant's commercial product is Vtama (tapinarof) for plaque psoriasis and atopic dermatitis (launched 2022) — a first-in-class aryl hydrocarbon receptor agonist that provides steroid-free topical treatment. Roivant also owns the healthcare technology company Proteovant (protein degradation) and has invested in multiple therapeutic areas through its Vant structure.	Merus N.V. is a Dutch clinical-stage oncology company pioneering bispecific antibodies — antibodies that simultaneously bind two different molecular targets — using its proprietary Biclonics technology platform. Traditional antibodies target one antigen; bispecific antibodies can bridge two different antigens (e.g., a tumor antigen and an immune cell receptor), potentially creating synergistic therapeutic effects not possible with single-target antibodies. Merus's most advanced clinical program is Zenocutuzumab (Zeno), a bispecific antibody targeting HER2 and HER3 for tumors harboring NRG1 gene fusions — a rare cancer driver in lung, pancreatic, and other cancers where NRG1 fusion activates the HER3/HER2 signaling pathway. Merus has multiple partnerships with major pharmaceutical companies (Incyte, Lilly) for bispecific antibody development.
Investor focus	Investors track Vtama's commercial launch performance (prescription and revenue growth), the value of Roivant's portfolio of Vant interests, Immunovant's IMVT-1402 FcRn inhibitor program in myasthenia gravis and other autoimmune diseases, and Roivant's cash position.	Investors track Zenocutuzumab's clinical development for NRG1 fusion cancers (NRG1 fusions are rare but represent a significant unmet need), partnership revenue from Incyte and Lilly collaborations, and the broader Biclonics pipeline progress.

ROIV strengths

→Vtama provides a commercial revenue anchor while the pipeline matures — Vtama's commercial launch in 2022-2023 in plaque psoriasis and expansion into atopic dermatitis provides Roivant with actual commercial revenue, reducing the pure-clinical-stage risk profile
→Immunovant's IMVT-1402 represents a potentially significant franchise in FcRn inhibition — IMVT-1402 targets FcRn (neonatal Fc receptor), which recycles IgG antibodies including pathogenic autoantibodies in myasthenia gravis, thyroid eye disease, and other autoimmune diseases; FcRn inhibitors are proving to be a high-value category
→Vant structure allows specialized focus and independent capitalization across multiple therapeutic areas — each Vant can raise its own capital (diluting Roivant's percentage but accessing non-dilutive capital for Roivant's balance sheet), attract specialized management talent, and make focused decisions without the complexity of a single giant pharma company

MRUS strengths

→Zenocutuzumab addresses NRG1 fusion cancers — a rare but previously undruggable cancer driver — with a first-in-class approach — NRG1 gene fusions are found in approximately 1-3% of cancers across multiple tumor types; NRG1 fusions activate the HER2/HER3 pathway; Zenocutuzumab's bispecific design blocks both HER2 (which HER3 signals through) and HER3 (the direct NRG1 receptor), providing particularly effective pathway blockade
→Major pharmaceutical partnerships validate Biclonics technology and provide non-dilutive capital — Merus's partnerships with Incyte (for MCLA-129, a bispecific antibody in oncology) and Eli Lilly (for multiple bispecific programs) represent validation of Biclonics technology and provide milestone payments and royalty rights
→Biclonics platform generates multiple proprietary and partnered programs — Merus can generate bispecific antibodies against diverse target combinations; the platform approach creates an opportunity to build a multi-program pipeline across oncology targets beyond Zenocutuzumab

Risks to watch — ROIV

→Vtama commercial launch has been below initial revenue expectations — Vtama's uptake has faced competitive pressure from existing psoriasis biologics and the novelty challenge of a new steroid-free topical treatment; slower-than-expected commercial ramp is a near-term headwind
→Vant model creates complexity for investors valuing the combined entity — Roivant's value is the sum of stakes in multiple Vants plus Vtama commercial, minus Roivant's holding company costs; this complex sum-of-parts valuation is difficult to model and may result in a 'conglomerate discount'
→Competition in autoimmune disease from established biologics and newer entrants is intense — Vtama competes with dupilumab (Dupixent), abrocitinib, upadacitinib, and multiple other approved therapies for atopic dermatitis

Risks to watch — MRUS

→NRG1 fusion cancers are rare, limiting the potential revenue opportunity for Zenocutuzumab — while NRG1 fusion represents a genuine unmet need, the prevalence (approximately 1-3% of cancer patients) limits the commercial market size; Zeno would require premium pricing to be commercially viable
→Bispecific antibody field is highly competitive with major pharma investing heavily — Johnson & Johnson, Roche, Amgen, AstraZeneca, and many others have large bispecific antibody programs; competition for the most valuable targets is intense
→Partnership dependency means some value is created for partners rather than wholly for Merus shareholders — partnered programs with Incyte and Lilly share economic value; if partnered programs are the most successful, Merus shareholders receive only royalties/milestones rather than full commercial revenue

Frequently asked questions

Traditional antibodies: monoclonal antibodies (mAbs) are laboratory-produced proteins that mimic the immune system's antibody function; a mAb binds to exactly one antigen (molecular target); approved antibody drugs include trastuzumab (Herceptin, binds HER2), pembrolizumab (Keytruda, binds PD-1), and adalimumab (Humira, binds TNF-alpha); mAbs have been enormously successful but are limited to one target per molecule. Bispecific antibodies: engineered to bind two different molecular targets simultaneously using a single antibody molecule; bispecific antibodies can be designed to: simultaneously block two signaling pathways (synergistic pathway blockade); recruit immune cells to kill cancer cells (one arm binds tumor antigen, one arm binds CD3 on T cells — T cell engagers); bridge two cancer surface proteins to inhibit protein complex formation; the dual-binding capability can generate pharmacology not possible with two separate single-target antibodies. Clinical successes: blinatumomab (Blincyto, Amgen) is a bispecific T-cell engager (BiTE) approved for B-cell acute lymphoblastic leukemia; amivantamab (Rybrevant, J&J) is a bispecific targeting EGFR and MET approved for NSCLC; these approvals validated the bispecific approach and opened drug development interest significantly. Manufacturing challenge: producing bispecific antibodies is technically more complex than monoclonal antibodies because an antibody has two 'arms' that must each bind the correct target — ensuring the two arms are correctly assembled requires specialized technology. Merus's Biclonics technology: Merus's Biclonics platform ensures correct assembly of bispecific antibodies using a proprietary 'common light chain' approach — by designing both antibody arms to share the same light chain, Merus ensures correct bispecific assembly without the manufacturing complexity of other bispecific approaches.

AI Prediction SignalNext 5 trading days

Members only

ROIV

+2.8%BUY

MRUS

+1.1%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

More comparisons